Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Progression-free survival: meaningful or simply measurable?

× No keyword cloud information.

97 in total

1. Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors: Boris Freidlin; Richard F Little; Edward L Korn
Journal: J Natl Cancer Inst Date: 2015-08-18 Impact factor: 13.506

2. Detecting overall survival benefit derived from survival postprogression rather than progression-free survival.

Authors: Satoshi Morita; Kentaro Sakamaki; Guosheng Yin
Journal: J Natl Cancer Inst Date: 2015-05-08 Impact factor: 13.506

3. The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials.

Authors: Jean-Marie Gibson; Saeed Alzghari; Chul Ahn; Holly Trantham; Ninh M La-Beck
Journal: Oncologist Date: 2013-07-23

4. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).

Authors: Jun Yin; Betsy LaPlant; Geoffrey L Uy; Guido Marcucci; William Blum; Richard A Larson; Richard M Stone; Sumithra J Mandrekar
Journal: Blood Adv Date: 2019-06-11

Review 5. Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development.

Authors: Bengt Jönsson
Journal: Mol Oncol Date: 2014-10-23 Impact factor: 6.603

Review 6. Endpoints and cutpoints in head and neck oncology trials: methodical background, challenges, current practice and perspectives.

Authors: Marcus Hezel; Kathrin von Usslar; Thiemo Kurzweg; Balazs B Lörincz; Rainald Knecht
Journal: Eur Arch Otorhinolaryngol Date: 2015-01-09 Impact factor: 2.503

7. Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.

Authors: Meletios A Dimopoulos; Maria T Petrucci; Robin Foà; John Catalano; Martin Kropff; Evangelos Terpos; Jingshan Zhang; Lara Grote; Christian Jacques; Antonio Palumbo
Journal: Haematologica Date: 2015-04-03 Impact factor: 9.941

8. A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials.

Authors: Kathleen Ruchalski; Marta Braschi-Amirfarzan; Michael Douek; Victor Sai; Antonio Gutierrez; Rohit Dewan; Jonathan Goldin
Journal: Radiol Imaging Cancer Date: 2021-05

9. Overall survival in non-small cell lung cancer-what is clinically meaningful?

Authors: Klaus Fenchel; Ludger Sellmann; Wolfram C M Dempke
Journal: Transl Lung Cancer Res Date: 2016-02

10. Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer.

Authors: Huiwei Qi; Sen Jiang; Dong Yu; Huijuan Ni; Qiong Hu; Jie Zhang
Journal: Med Oncol Date: 2015-10-23 Impact factor: 3.064